Results 21 to 30 of about 1,158 (177)

Teduglutide treatment during breast feeding in a patient with intestinal failure: a case report [PDF]

Frontiers in Nutrition
Successful pregnancy and breast feeding during intravenous treatment for advanced intestinal failure (IF) is possible with careful surveillance and appropriate adjustment of the nutritional regimen.
Jan Lillienau, Elin Nilsson, Alexandra Vulcan, Åke Nilsson   +3 more
doaj   +2 more sources

Development of a Mechanism of Action-Reflective Cell-Based Reporter Gene Assay for Measuring Bioactivities of Therapeutic Glucagon-like Peptide-2 Analogues [PDF]

Molecules
Glucagon-like peptide-2 (GLP-2) is a gut hormone that plays a pivotal role in regulating intestinal epithelial cell growth and function, making it a promising therapeutic agent for intestinal damage and bone-related diseases. Nonetheless, the therapeutic
Xiaoming Zhang, Chunyan Li, Zhe Deng, Chenggang Liang, Jing Li   +4 more
doaj   +2 more sources

Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome [PDF]

Therapeutics and Clinical Risk Management, 2018
Kristina S Chen,1 Jipan Xie,2 Wenxi Tang,3 Jing Zhao,4 Palle B Jeppesen,5 James E Signorovitch4 1Outcomes Research and Epidemiology, Shire Human Genetic Therapies, Inc., Cambridge, MA, USA; 2Analysis Group, Inc., Los Angeles, CA, USA; 3Analysis Group ...
Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE   +5 more
doaj   +2 more sources

Predictors of response and enteral autonomy in children with short bowel syndrome treated with teduglutide: a real-life multicentre cohort studyResearch in context [PDF]

EClinicalMedicine
Summary: Background: Teduglutide (TED), a glucagon-like peptide 2 analogue licensed for children with short bowel syndrome (SBS), is increasingly used in the attempt to augment intestinal absorption and lower parenteral nutrition (PN) needs.
Lorenzo Norsa, Arianna Ghirardi, Esther Ramos Boluda, Anat Guz-Mark, Iva Hojsak, Johannes Hilberath, Ilse Juia Broekaert, Rocío González Sacristán, Antonella Lezo, Paula Guerra, Pierre Poinsot, Cecile Lambe, Lorenzo D'Antiga   +12 more
doaj   +2 more sources

Off-label teduglutide therapy in non-intestinal failure patients with chronic malabsorption [PDF]

, 2019
Background: Teduglutide, a glucagon-like peptide 2 (GLP-2) analogue, has demonstrated efficacy in treating adult patients with short bowel syndrome (SBS) and dependence on parenteral nutrition (PN), but its role in chronic malabsorptive states that do ...
Alvin T. George (7923575), Betty H. Li (7923578), Robert E. Carroll (7923581)   +2 more
core   +7 more sources

Outcomes and adverse effects of teduglutide treatment with periodic withdrawal in pediatric short bowel patients. [PDF]

J Pediatr Gastroenterol Nutr
Abstract Objectives We evaluated the efficacy and safety of teduglutide in a real‐world cohort in which national reimbursement policies required treatment interruptions. The primary outcomes were reduction in parenteral support (PS) and treatment‐related adverse effects, and the secondary outcome was the impact of the mandated withdrawal periods ...
Gunnar R, Mutanen A, Pakarinen MP, Merras-Salmio L.   +3 more
europepmc   +2 more sources

Targeted therapy of short-bowel syndrome with teduglutide: the new kid on the block

Clinical and Experimental Gastroenterology, 2014
Kishore Vipperla,1 Stephen J O'Keefe2 1Division of General Internal Medicine, University of Pittsburgh Medical Center, 2Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA ...
Vipperla K, O’Keefe SJ
doaj   +1 more source

Quality of life for pediatric patients with short bowel syndrome-associated intestinal failure treated with teduglutide. [PDF]

J Pediatr Gastroenterol Nutr
Abstract Objectives The complex care needs of pediatric patients with short bowel syndrome‐associated intestinal failure (SBS‐IF) can negatively impact the health‐related quality of life (HRQoL) of patients and their caregivers. We assessed the impact of teduglutide on HRQoL of pediatric patients with SBS‐IF.
Wendel D, Wales PW, Kocoshis S, Venick R, Carter B, Cohran V, Matthews C, Raphael BP, Robinson I, Hill S.   +9 more
europepmc   +2 more sources

Novel variant and enteroendocrine hormone deficiency in a patient with proline and glutamate‐rich protein with a coiled coil domain 1 (PERCC1) associated enteropathy: New diagnostic and therapeutic insights [PDF]

JPGN Rep
Abstract Proline and glutamate‐rich protein with a coiled coil domain 1 (PERCC1)‐associated enteropathy is a rare monogenic congenital diarrhea due to defective enteroendocrine cells (EECs). We describe a 6‐year‐old female with intestinal failure since birth.
Di Chio T, Gattini D, Belza C, Siddiqui I, Hartmann B, Benchimol M, Zhang S, Warner N, Muise A, Avitzur Y.   +9 more
europepmc   +2 more sources

PERCC1-associated enteropathy: Diagnostic challenges and enteral autonomy achieved with teduglutide. [PDF]

JPGN Rep
Abstract Congenital diarrheas and enteropathies (CODE) are rare inherited disorders characterized by early‐onset intractable diarrhea. Though progress has been made in elucidating the genetic basis of CODE, much remains to be discovered. Another challenge is the lack of curative therapies—treatment is primarily supportive including enteral and ...
Tran A, Nguyen V, Huynh P.
europepmc   +2 more sources